![conference banner](/images/conference-banner.jpeg)
Abstract
Epidemiological studies have linked platelet hyperactivity with an increased risk of vascular events. Even more convincing is the evidence from appropriately designed clinical trials showing that antiplatelet agents decrease the risk of vascular events (e.g. myocardial infarction, MI and stroke). These findings are compatible with the known thrombotic action of platelets. A considerable limitation in platelet research is the absence of a reliable, universally accepted marker of platelet activity. Therefore, it is difficult to reliably identify the ‘high risk patient’ and/or evaluate the efficacy of any administered treatment other than by calculating event rates over a period of time. This review will focus on the preventive aspects of antiplatelet intervention while also briefly considering the assessment of platelet hyperactivity and the mechanisms involved in platelet-induced thrombosis.
Keywords: Platelet, aggregation, thrombosis, aspirin, clopidogrel, myocardial infarction, stroke
Current Pharmaceutical Design
Title: Platelets and Vascular Risk: An Option for Treatment
Volume: 13 Issue: 16
Author(s): I. A. Jagroop, A. I. Kakafika and D. P. Mikhailidis
Affiliation:
Keywords: Platelet, aggregation, thrombosis, aspirin, clopidogrel, myocardial infarction, stroke
Abstract: Epidemiological studies have linked platelet hyperactivity with an increased risk of vascular events. Even more convincing is the evidence from appropriately designed clinical trials showing that antiplatelet agents decrease the risk of vascular events (e.g. myocardial infarction, MI and stroke). These findings are compatible with the known thrombotic action of platelets. A considerable limitation in platelet research is the absence of a reliable, universally accepted marker of platelet activity. Therefore, it is difficult to reliably identify the ‘high risk patient’ and/or evaluate the efficacy of any administered treatment other than by calculating event rates over a period of time. This review will focus on the preventive aspects of antiplatelet intervention while also briefly considering the assessment of platelet hyperactivity and the mechanisms involved in platelet-induced thrombosis.
Export Options
About this article
Cite this article as:
Jagroop A. I., Kakafika I. A. and Mikhailidis P. D., Platelets and Vascular Risk: An Option for Treatment, Current Pharmaceutical Design 2007; 13 (16) . https://dx.doi.org/10.2174/138161207780831383
DOI https://dx.doi.org/10.2174/138161207780831383 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of LncRNA MIAT in Diabetic Complications
Current Medicinal Chemistry Current Hot Potatoes in Atrial Fibrillation Ablation
Current Cardiology Reviews Use of Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Relation to Cardiovascular Events. A Systematic Pharmacoepidemiological Review
Current Vascular Pharmacology Liver Enzymes: Potential Cardiovascular Risk Markers?
Current Pharmaceutical Design Pharmacotherapy of Obesity - Benefit, Bias and Hyperbole
Current Medicinal Chemistry Gene-Gene and Gene-Clinical Factors Interaction in Acute Myocardial Infarction: A New Detailed Risk Chart
Current Pharmaceutical Design Pituitary Dysfunction as a Cause of Cardiovascular Disease
Current Pharmaceutical Design A Survey on the Usage of Supplements in Canadian Patients Living with HIV
Current HIV Research Discovery of New Cardiovascular Hormones for the Treatment of Congestive Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Transdermal Delivery of Captopril and Metoprolol Tartrate with Microneedles
Drug Delivery Letters Mending a Broken Heart: Bioengineered Patches and Scaffolds for Cardiac Repair
Recent Patents on Biomedical Engineering (Discontinued) Adverse Effects of Statins - Mechanisms and Consequences
Current Drug Safety Clinical Drug Development in Thromboembolic Diseases: Regulatory and Methodological Approach
Current Drug Discovery Technologies Paget’s Disease of Bone and Cardiovascular Risk: A Pilot Study
Current Vascular Pharmacology Avian Cytokines - An Overview
Current Pharmaceutical Design Nanotechnology and Atherosclerosis Imaging: Emerging Diagnostic and Therapeutic Applications
Recent Patents on Cardiovascular Drug Discovery In Search for the Troponin of the Kidney
Current Medicinal Chemistry Almonds: A Source of Healthy Molecules or a Risk of Aflatoxins Human Exposure?
Current Nutrition & Food Science Novel Oral Anticoagulants: Recommendations for Patient Evaluation, Treatment Initiation, Follow-up and Perioperative Management
Cardiovascular & Hematological Disorders-Drug Targets Antithrombotic Therapy in Carotid Artery Disease
Current Pharmaceutical Design